Incidence of HIV Lower With Twice-Yearly Subcutaneous Lenacapavir
By Elana Gotkine HealthDay Reporter
TUESDAY, Dec. 3, 2024 -- In a population of cisgender men, transgender women, transgender men, and gender-nonbinary persons, the incidence of HIV is lower with receipt of twice-yearly subcutaneous lenacapavir compared with daily oral emtricitabine-tenofovir disoproxil fumarate (F/TDF), according to a study published online Nov. 27 in the New England Journal Medicine.
Colleen F. Kelley, M.D., M.P.H., from the Hope Clinic of the Emory University School of Medicine in Decatur, Georgia, and colleagues randomly assigned cisgender men, transgender women, transgender men, and gender-nonbinary persons to receive subcutaneous lenacapavir every 26 weeks or daily oral F/TDF in a 2:1 ratio in a phase 3 trial.
The modified intention-to-treat analysis included 3,265 participants: 2,183 were assigned to lenacapavir and 1,088 to F/TDF. The researchers found that HIV infections occurred in two and nine participants in the lenacapavir and F/TDF groups, respectively (0.10 and 0.93, respectively, per 100 person-years). In the screened population (4,634 participants), the background incidence was 2.37 per 100 person-years. In the lenacapavir group, the incidence of HIV infection was significantly lower than the background incidence and the incidence in the F/TDF group (incidence rate ratios, 0.04 and 0.11, respectively). There were no safety concerns reported. Overall, 1.2 and 0.3 percent of the lenacapavir and F/TDF groups, respectively, discontinued the trial regimen due to injection site reactions.
"Twice-yearly lenacapavir offers an efficacious choice for prevention of HIV infection, which may increase preexposure prophylaxis uptake," the authors write.
Several authors disclosed ties to biopharmaceutical companies, including Gilead Sciences, which manufactures lenacapavir and funded the study.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted December 2024
Read this next
Attrition Rates High Among Lesbian, Gay, Bisexual Medical Students
WEDNESDAY, June 11, 2025 -- Medical school attrition rates are high among lesbian, gay, or bisexual (LGB) medical students, according to a research letter published online June 10...
Initiation of HIV PrEP in Young Adults Rose in Recent Years
TUESDAY, June 3, 2025 -- Dispensing and initiation of HIV preexposure prophylaxis (PrEP) among young adults increased from 2016 through 2023, according to a study published online...
ACP Issues Clinical Guideline for Statin Use in Persons With HIV
THURSDAY, May 29, 2025 -- In a clinical guideline issued by the American College of Physicians and published online May 27 in the Annals of Internal Medicine, recommendations are...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.